WORK Medical Technology Group LTD (WOK) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 62.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 216
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 48,942,080
• 10 Day Avg. Volume: 56,856
• 30 Day Avg. Volume: 62,787
• PEG Ratio: 0.07
• Price to Book (P/B): 0.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: 0.67
• Enterprise Value/Gross Profit: 9.11
• Enterprise Value/Ebitda: -5.08
• 1Y Price Target: $1.00
• Price Target Upside: 20.48% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: $0.50 ▼(-39.76%Downside)

The overall stock score for WORK is primarily impacted by its poor financial performance, which is characterized by declining revenues and profitability, negative cash flows, and high leverage. Technical analysis provides some positive short-term signals, but the long-term outlook remains weak. The absence of valuation metrics further complicates the assessment. Improvements in financial performance and clearer valuation data could enhance the stock's attractiveness.

WORK Medical Technology Group LTD Business Overview & Revenue Model

Company Description

WORK Medical Technology Group LTD (WOK) is a healthcare technology company specializing in the development and distribution of innovative medical devices and software solutions. The company operates in the medical technology sector, focusing on products that enhance diagnostic accuracy and improve patient outcomes. WOK's core offerings include advanced imaging systems, patient monitoring devices, and healthcare data management software designed to support medical professionals in delivering efficient and effective care.

How the Company Makes Money

WOK generates revenue primarily through the sale of its medical devices and software solutions to healthcare providers, hospitals, and clinics. The company employs a business model that includes direct sales, leasing options, and service agreements for maintenance and updates of its equipment. Additionally, WOK earns income from software licensing fees and subscription-based services for its data management platforms. Strategic partnerships with healthcare institutions and collaborations with research organizations also contribute to the company's revenue by expanding its market reach and enhancing product innovation.

WORK Medical Technology Group LTD Financial Statement Overview

Summary

WORK Medical Technology Group LTD faces significant financial challenges, with declining revenues and profitability impacting overall performance. High leverage and negative cash flows present additional risks, though the company shows some financial flexibility through financing activities. Strategic adjustments may be necessary to address operational inefficiencies and improve financial stability.

Income Statement

The company has experienced a significant decline in revenue over the past few years, with a notable drop from $52.5M in 2020 to $11.5M in 2024. Gross profit margin has decreased, reflecting challenges in maintaining profitability as net profit turned negative. The negative EBIT and EBITDA margins in the latest year signify operational difficulties. Revenue growth has been negative for consecutive years, indicating a contraction in business operations.

Balance Sheet

The company maintains a moderate equity ratio, suggesting a balanced use of debt and equity financing. However, the debt-to-equity ratio is somewhat high, reflecting increased leverage which could pose risks if not managed properly. The return on equity has turned negative in recent periods, highlighting profitability issues impacting shareholders' returns.

Cash Flow

Free cash flow has been negative in recent years, pointing to cash management challenges. The operating cash flow to net income ratio is also negative, indicating inefficiencies in converting income into cash. Despite these issues, the company has managed some cash influx through financing activities, albeit not enough to cover operating and investing cash outflows.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	11.51M	13.57M	19.71M	45.86M	52.53M
Gross Profit	2.87M	4.14M	4.42M	8.64M	10.85M
EBITDA	-2.65M	2.08M	4.72M	11.87M	4.75M
Net Income	-3.49M	112.03K	865.21K	5.96M	1.16M
Balance Sheet
Total Assets	36.25M	29.96M	25.54M	30.66M	56.20M
Cash, Cash Equivalents and Short-Term Investments	6.56M	1.60M	731.18K	508.71K	200.40K
Total Debt	13.47M	9.10M	6.30M	6.60M	4.05M
Total Liabilities	20.18M	18.97M	14.35M	19.26M	50.27M
Stockholders Equity	13.19M	9.88M	10.00M	10.04M	4.90M
Cash Flow
Free Cash Flow	-11.49M	1.63M	-4.27M	-7.24M	9.65M
Operating Cash Flow	-2.23M	2.21M	-2.26M	-7.18M	27.20M
Investing Cash Flow	-9.06M	-583.30K	-1.35M	-60.00K	-16.84M
Financing Cash Flow	15.66M	-728.72K	3.57M	7.99M	-10.28M

WORK Medical Technology Group LTD Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.83
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WOK, the sentiment is Positive. The current price of 0.83 is above the 20-day moving average (MA) of 0.77, above the 50-day MA of 0.75, and below the 200-day MA of 2.60, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 61.06 is Neutral, neither overbought nor oversold. The STOCH value of 70.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for WOK.

WORK Medical Technology Group LTD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	67 Neutral	$12.40M	1.05	7.10%	―	-0.19%	-18.41%
Sector *	66 Neutral	€6.46B	18.46	-1.30%	2.24%	-0.15%	-41.32%
WOK	48 Neutral		―		―	―	―
FEMY	40 Neutral	$29.27M	―	-239.87%	―	61.97%	-6.89%
MLSS	40 Underperform	$46.31M	―	-88.36%	―	-9.13%	30.04%